DECISION related activities at EASL Congress 2026
Wednesday, 27th May 2026, 13:45 – 14:15
DECISION Networking Session at the Cirrhosis and Complications Track Hub
Agenda:
- Brief intro to DECISION project
Pierre-Emmanuel Rautou, DECISION coordinator
- New DECISION research on ACLF
Frank Uschner
- Epigenomics on patients with acute decompensated cirrhosis
Estefania Huergo Iglesias
- Discussion + Conclusion
Pierre-Emmanuel Rautou
DECISION members at EASL Congress: Talks
Wednesday, 27 May
| Time | Talk / Session | Speaker(s) | Part of Session | Room |
| 15:15 – 15:25 | Patient/provider communication | Marko Korenjak | Interprofessional Forum: Patient & Advocate Forum: Communicating with patients and families – Collaborations with the care team (14:45 – 16:15 | Bréchot – Hall 8.0 |
Thursday, 28 May
| Time | Talk / Session | Speaker(s) | Part of Session | Room |
| 08:30 – 08:50 | Overview of JHEP Reports performance | Virginia Hernández-Gea | JHEP Reports Symposium: Performance, highlights and tips for publication (08:30 – 09:45) | Burroughs – Hall 8.0 |
| 12:00 – 12:15 | Transjugular intrahepatic portosystemic shunt for refractory hepatic hydrothorax in cirrhosis: a multicenter European study | Carlo Alessandria | General Session I (10:30 – 12:30) | Tiribelli – Hall 8.1 |
| 14:45 – 15:05 | From cirrhosis to cACLD through modern diagnostics | Joan Genesca | Postgraduate Course: Diagnostics in liver diseases – Advanced chronic liver disease (14:45 – 16:00 | Tiribelli – Hall 8.1 |
Friday, 29 May
| Time | Talk / Session | Speaker(s) | Part of Session | Room |
| 08:30 – 09:45 | Do’s and Don’ts in bridging your patient with ACLF grade 2 and 3 to liver transplant | Thierry Gustot (Co-Chair) | Rizzetto – Hall 8.0 | |
| 10:45 – 11:00 | RNA editing for the treatment of alpha-1 antitrypsin deficiency (AATD) | Pavel Strnad | General Session II | Tiribelli – Hall 8.1 |
| 15:00 – 16:15 | Virginia Hernández-Gea (Co-Chair) Pierre-Emmanuel Rautou (Co-Chair and presenter) | EASL/VALDIG symposium: Consensus on endpoints in PSVD | Mondelli – Hall 8.0 | |
| 15:45 – 15:55 | Endpoints for clinical studies in PSVD | Virginia Hernández-Gea (Co-Chair) Pierre-Emmanuel Rautou (Co-Chair and presenter) | EASL/VALDIG symposium: Consensus on endpoints in PSVD | Mondelli – Hall 8.0 |
| 18:30 – 18:45 | Connected patients (Wearables, implantable sensors, remote follow-up) | Rajeshwar Mookerjee | Postgraduate Course: Diagnostics in liver diseases – Shaping the Future (17:45 – 19:15) | Tiribelli – Hall 8.1 |
Saturday, 30 May
| Time | Talk / Session | Speaker(s) | Part of Session | Room |
| 08:30 – 09:45 | EASL/EF-CLIF: The Road Ahead – Horizon scanning in cirrhosis and portal hypertension – Ongoing phase 3 RCTs | Jonel Trebicka (Co-Chair) | Rizzetto – Hall 8.0 | |
| 09:24 – 09:39 | ACLF | Javier Fernández | EASL/EF-CLIF: The Road Ahead – Horizon scanning in cirrhosis and portal hypertension – Ongoing phase 3 RCTs | Rizzetto – Hall 8.0 |
| 10:15 – 11:15 | Meet-the-Experts: Liquid biopsy strategies for liver diseases | Pierre-Emmanuel Rautou (Co-Chair) | Meet-the-Experts 1 – Hall 8.0 |
DECISION members at EASL: Posters
Wednesday, 27 May
Poster Session: Cirrhosis and its complications: Other clinical complications except ACLF and critical illness
- Pre-treatment serum albumin concentration predicts clinical outcomes in patients with cirrhosis receiving long-term albumin Presenter: Enrico Pompili
- Development of a composite biomarker to predict risk of AKI and mortality following an acute decompensation of cirrhosis Presenter: Olivia Greenham
- Remote patient monitoring reduces liver-related hospital readmissions in patients with acutely decompensated cirrhosis Presenter: Alberto Calleri
Poster Session: MASLD: Diagnostics and non-invasive assessment
- The sequential use of LiverPRO and ADAPT enhances fibrosis detection in at-risk populations Presenter: Diana Julie Leeming
Thursday, 28 May
Poster Session: Rare liver diseases (including paediatric and genetic) – Clinical
- Fazirsiran treatment reduces serum biomarkers that predict major adverse liver outcomes in patients with alpha-1 antitrypsin deficiency-associated liver disease Presenter: Pavel Strnad
- Novel serum proteomic signatures associated with disease burden in alpha-1 antitrypsin deficiency-associated liver disease Presenter: Pavel Strnad
Poster Session: Portal Hypertension (cirrhosis and non-cirrhosis)
- Liver and spleen stiffness measurements by vibration – controlled transient elastography predict liver-related outcomes of patients with porto-sinusoidal vascular disorder Presenter: Lucile Moga
Friday, 29 May
Poster Session: Liver transplantation and hepatobiliary surgery – Clinical
- Continuous glucose monitoring in liver transplant recipients in the intensive care unit: a randomized clinical trial cohort Presenter: Richie Alexander Inge Cox
- Incidence risk factors and outcomes of cytomegalovirus infection after liver transplantation Presenter: Maximilian Brol
Poster Session: – Fibrosis / Stellate cell biology
- Constitutive MAS1 G protein-coupled receptor participates in the pathogenesis of liver fibrosis Presenter: Sabine Klein
Poster Session: Cirrhosis and its complications: Experimental and pathophysiology
- Title: Systemic markers of fibroblast- and immune cell activity in post-TIPS endotyping within patients with severe clinical evolution Presenter: Diana Julie Leeming
Saturday, 30 May
Poster Session: General Hepatology (including non-invasive liver assessment)
- Mortality prediction using non-invasive fibrosis scores independent of chronic liver disease in patients with COVID-19 Presenter: Maximilian Brol
All posters will be displayed in Poster Area – Hall 7.